Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Parallel Group, Randomised, Placebo Controlled Study of Efficacy and Safety of Circadin® 2 mg in the Treatment of Insomnia Patients With Low Endogenous Melatonin

NCT00397189 is registered in ClinicalTrials.gov with Neurim Pharmaceuticals Ltd. as lead sponsor.

NCT NCT00397189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00397189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Parallel Group, Randomised, Placebo Controlled Study of Efficacy and Safety of Circadin® 2 mg in the Treatment of Insomnia Patients With Low Endogenous Melatonin
Lead sponsor
Neurim Pharmaceuticals Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2006
Completion date
April 30, 2009
Enrollment
930 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary insomnia